Cargando…

SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia

Philadelphia-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk subtype of B-cell ALL characterized by a gene expression profile resembling Philadelphia chromosome–positive ALL (Ph(+) ALL) in the absence of BCR-ABL1. Tyrosine kinase–activating fusions, some involving ABL1, are recurren...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, Lauren M., Hediyeh-zadeh, Soroor, Sadras, Teresa, Huckstep, Hannah, Sandow, Jarrod J., Bartolo, Ray C., Kosasih, Hansen J., Davidson, Nadia M., Schmidt, Breon, Bjelosevic, Stefan, Johnstone, Ricky, Webb, Andrew I., Khaw, Seong L., Oshlack, Alicia, Davis, Melissa J., Ekert, Paul G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Lymphoid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006296/ https://www.ncbi.nlm.nih.gov/pubmed/35061886 http://dx.doi.org/10.1182/bloodadvances.2021006076

Ejemplares similares

Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia
por: Tirtakusuma, Ricky, et al.
Publicado: (2022)

Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma
por: Eertink, J. J., et al.
Publicado: (2023)

Prognostic model using (18)F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma
por: Driessen, Julia, et al.
Publicado: (2023)

Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2021)

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2023)

Comparative efficacy and tolerability of novel agents vs chemotherapy in relapsed and refractory T-cell lymphomas: a meta-analysis
por: Shafagati, Nazila, et al.
Publicado: (2022)

Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis
por: Ikeda, Masato, et al.
Publicado: (2022)

Immunochemotherapy or chemotherapy alone in primary central nervous system lymphoma: a National Cancer Database analysis
por: Ollila, Thomas A., et al.
Publicado: (2023)

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
por: Liang, Emily C., et al.
Publicado: (2023)

Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia
por: Ferguson, Daniel C., et al.
Publicado: (2022)

Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma
por: Eertink, Jakoba J., et al.
Publicado: (2022)

Increased prevalence of CRLF2 rearrangements in obesity-associated acute lymphoblastic leukemia
por: Mittelman, Steven D., et al.
Publicado: (2021)

Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia
por: Bridges, Cory Seth, et al.
Publicado: (2022)

Cytokine receptor IL27RA is an NF-κB–responsive gene involved in CD38 upregulation in multiple myeloma
por: Brownlie, Rebecca J., et al.
Publicado: (2023)

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
por: Cherng, Hua-Jay J., et al.
Publicado: (2022)

Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia
por: Parvin, Salma, et al.
Publicado: (2023)

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies
por: Thomalla, D., et al.
Publicado: (2022)

Genome-wide CRISPR/Cas9 screening identifies determinant of panobinostat sensitivity in acute lymphoblastic leukemia
por: Jiang, Chuang, et al.
Publicado: (2022)

Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry
por: Jones, David A., et al.
Publicado: (2022)

Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma
por: Bolomsky, Arnold, et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
por: Bhaskar, Shakthi T., et al.
Publicado: (2022)

Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL
por: Antoszewski, Mateusz, et al.
Publicado: (2022)

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2023)

Retrospective characterization of nodal marginal zone lymphoma
por: Stuver, Robert, et al.
Publicado: (2023)

Diffuse large B-cell lymphomas have spatially defined, tumor immune microenvironments revealed by high-parameter imaging
por: Wright, Kyle T., et al.
Publicado: (2023)

Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study
por: Böttcher, Sebastian, et al.
Publicado: (2022)

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma
por: Neelapu, Sattva S., et al.
Publicado: (2021)

Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study
por: Brink, Mirian, et al.
Publicado: (2022)

A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma
por: van Bladel, Diede A. G., et al.
Publicado: (2023)

Extracellular vesicle proteomic analysis leads to the discovery of HDGF as a new factor in multiple myeloma biology
por: Hoelzinger, Dominique B., et al.
Publicado: (2022)

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022)

Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
por: Tun, Aung M., et al.
Publicado: (2022)

Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
por: Facon, Thierry, et al.
Publicado: (2021)

Sézary syndrome originates from heavily mutated hematopoietic progenitors
por: Harro, Carly M., et al.
Publicado: (2023)

TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy
por: Johnson, William T., et al.
Publicado: (2023)

Single-cell analysis of Sézary syndrome reveals novel markers and shifting gene profiles associated with treatment
por: Borcherding, Nicholas, et al.
Publicado: (2022)

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma
por: Cherng, Hua-Jay J., et al.
Publicado: (2022)

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma
por: Heynen, Guus J. J. E., et al.
Publicado: (2022)

Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey
por: Harkins, R. Andrew, et al.
Publicado: (2022)

Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL
por: Griffin, Rosalie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sgk217qnhjubtd77j3qv2dvbau